HDAC Inhibitor-Mediated Radiosensitization in Human Carcinoma Cells: A General Phenomenon?

Abstract

Historic deacetylase inhibitors (HDIs) have attracted considerable attention for anticancer therapy strategy. including radiosensitization Regarding a potential application of HDI as a radiosensitizer in the treatment of solid tumors, an important question is whether treatment efficacy would be Influenced by intrinsic differences between cancer cells, such as different histologic origin and status of ATM or p53. First we have observed the in vitro radiosensitization by Trichostatin A (TSA) on the broad spectrum of human tumor cell lines having different histologic origin such as HCT116 adenocarcinoma of colon. A549 adenocarcinoma of lung. HN-3 squamous cell carcinoma of head/neck, and HeLa squamous cacinoma of uterine cervix, using clonogenic assay. Next, we have systematically assessed the radiosensitization on the cell lines having different ATM or p53 status. We found that pretreatment of HDI consistently resulted in radiosensitization of all cell lines tested, though the sensitizer enhancement ratio of individual cell lines was variable We also observed that TSA-mediated radiosensitization was clearly influenced by p53 and ATM status of cells tested. The data presented here indicate that HDI enhances the radiation induced cell killing in the various cancer cells having intrinsic differences and may serve as a general strategy for enhancing tumor cell radiosensitivity These results have potential implications for the clinical utility of HDI in increasing the anticancer efficacy of radiation